Search

Your search keyword '"Kaita, K."' showing total 219 results
Start Over Author "Kaita, K."
219 results on '"Kaita, K."'

1. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

Author

Razavi-Shearer, D., Child, H., Razavi-Shearer, K., Voeller, A., Razavi, H., Buti, M., Tacke, F., Terrault, N., Zeuzem, S., Abbas, Z., Aghemo, A., Akarca, U.S., Al Masri, N., Alalwan, A., Blomé, M. Alanko, Jerkeman, A., Aleman, S., Kamal, H., Alghamdi, A., Alghamdi, M., Alghamdi, S., Al-Hamoudi, W., Ali, E., Aljumah, A., Altraif, I., Amarsanaa, J., Asselah, T., Baatarkhuu, O., Babameto, A., Ben-Ari, Z., Berg, T., Biondi, M., Braga, W., Brandão-Mello, C., Brown, R., Brunetto, M., Cabezas, J., Cardoso, M., Martins, A., Chan, H.L.Y., Cheinquer, H., Chen, C.-J., Yang, H.-I., Chen, P.-J., Chien, C.-H., Chuang, W.-L., Garza, L. Cisneros, Coco, B., Coffin, C., Coppola, N., Cornberg, M., Craxi, A., Crespo, J., Cuko, L., De Ledinghen, V., Duberg, A.-S., Etzion, O., Ferraz, M.L., Ferreira, P., Forns, X., Foster, G., Fung, J., Gaeta, G., García-Samaniego, J., Genov, J., Gheorghe, L., Gholam, P., Gish, R., Glenn, J., Hamid, S., Hercun, J., Hsu, Y.-C., Hu, C.-C., Huang, J.-F., Idilman, R., Jafri, W., Janjua, N., Jelev, D., Jia, J., Kåberg, M., Kaita, K., Kao, J.-H., Khan, A., Kim, D.Y., Kondili, L., Lagging, M., Lampertico, P., Lázaro, P., Lazarus, J.V., Lee, M.-H., Lim, Y.-S., Lobato, C., Macedo, G., Marinho, R., Marotta, P., Mendes-Correa, M.C., Méndez-Sánchez, N., Navas, M.-C., Ning, Q., Örmeci, N., Orrego, M., Osiowy, C., Pan, C., Pessoa, M., Piracha, Z., Pop, C., Qureshi, H., Raimondo, G., Ramji, A., Ribeiro, S., Ríos-Hincapié, C., Rodríguez, M., Rosenberg, W., Roulot, D., Ryder, S., Saeed, U., Safadi, R., Shouval, D., Sanai, F., Sanchez-Avila, J.F., Santantonio, T., Sarrazin, C., Seto, W.-K., Simonova, M., Tanaka, J., Tergast, T., Tsendsuren, O., Valente, C., Villalobos-Salcedo, J.M., Waheed, Y., Wong, G., Wong, V., Yip, T., Wu, J.-C., Yu, M.-L., Yuen, M.-F., Yurdaydin, C., and Zuckerman, E.

Published
2024
Full Text
View/download PDF

2. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

Author

Razavi-Shearer, D., primary, Child, H., additional, Razavi-Shearer, K., additional, Voeller, A., additional, Razavi, H., additional, Buti, M., additional, Tacke, F., additional, Terrault, N., additional, Zeuzem, S., additional, Abbas, Z., additional, Aghemo, A., additional, Akarca, U.S., additional, Al Masri, N., additional, Alalwan, A., additional, Blomé, M Alanko, additional, Jerkeman, A., additional, Aleman, S., additional, Kamal, H., additional, Alghamdi, A., additional, Alghamdi, M., additional, Alghamdi, S., additional, Al-Hamoudi, W., additional, Ali, E., additional, Aljumah, A., additional, Altraif, I., additional, Amarsanaa, J., additional, Asselah, T., additional, Baatarkhuu, O., additional, Babameto, A., additional, Ben-Ari, Z., additional, Berg, T., additional, Biondi, M., additional, Braga, W., additional, Brandão-Mello, C., additional, Brown, R., additional, Brunetto, M., additional, Cabezas, J., additional, Cardoso, M., additional, Martins, A., additional, Chan, H.L.Y., additional, Cheinquer, H., additional, Chen, C.-J., additional, Yang, H.-I., additional, Chen, P.-J., additional, Chien, C.-H., additional, Chuang, W.-L., additional, Garza, L Cisneros, additional, Coco, B., additional, Coffin, C., additional, Coppola, N., additional, Cornberg, M., additional, Craxi, A., additional, Crespo, J., additional, Cuko, L., additional, De Ledinghen, V., additional, Duberg, A.-S., additional, Etzion, O., additional, Ferraz, M.L., additional, Ferreira, P., additional, Forns, X., additional, Foster, G., additional, Fung, J., additional, Gaeta, G., additional, García-Samaniego, J., additional, Genov, J., additional, Gheorghe, L., additional, Gholam, P., additional, Gish, R., additional, Glenn, J., additional, Hamid, S., additional, Hercun, J., additional, Hsu, Y.-C., additional, Hu, C.-C., additional, Huang, J.-F., additional, Idilman, R., additional, Jafri, W., additional, Janjua, N., additional, Jelev, D., additional, Jia, J., additional, Kåberg, M., additional, Kaita, K., additional, Kao, J.-H., additional, Khan, A., additional, Kim, D.Y., additional, Kondili, L., additional, Lagging, M., additional, Lampertico, P., additional, Lázaro, P., additional, Lazarus, J.V., additional, Lee, M.-H., additional, Lim, Y.-S., additional, Lobato, C., additional, Macedo, G., additional, Marinho, R., additional, Marotta, P., additional, Mendes-Correa, M.C., additional, Méndez-Sánchez, N., additional, Navas, M.-C., additional, Ning, Q., additional, Örmeci, N., additional, Orrego, M., additional, Osiowy, C., additional, Pan, C., additional, Pessoa, M., additional, Piracha, Z., additional, Pop, C., additional, Qureshi, H., additional, Raimondo, G., additional, Ramji, A., additional, Ribeiro, S., additional, Ríos-Hincapié, C., additional, Rodríguez, M., additional, Rosenberg, W., additional, Roulot, D., additional, Ryder, S., additional, Saeed, U., additional, Safadi, R., additional, Shouval, D., additional, Sanai, F., additional, Sanchez-Avila, J.F., additional, Santantonio, T., additional, Sarrazin, C., additional, Seto, W.-K., additional, Simonova, M., additional, Tanaka, J., additional, Tergast, T., additional, Tsendsuren, O., additional, Valente, C., additional, Villalobos-Salcedo, J.M., additional, Waheed, Y., additional, Wong, G., additional, Wong, V., additional, Yip, T., additional, Wu, J.-C., additional, Yu, M.-L., additional, Yuen, M.-F., additional, Yurdaydin, C., additional, and Zuckerman, E., additional

Published
2023
Full Text
View/download PDF

7. Strategies to manage hepatitis C virus (HCV) disease burden

Author

Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balk, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergör, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Guimarães Pessôa, M., Hézode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Müllhaupt, B., Myers, R. P., Nemecek, V., vrehus, A. L. H., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., and Gower, E.

Published
2014
Full Text
View/download PDF

8. The present and future disease burden of hepatitis C virus (HCV) infection with todayʼs treatment paradigm

Author

Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., Akarca, U., Aleman, S., Balk, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Buti, M., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Örmeci, N., vrehus, A. L. H., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Müllhaupt, B., and Estes, C.

Published
2014
Full Text
View/download PDF

9. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Author

Bruggmann, P., Berg, T., vrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balk, İ., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hézode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Müllhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Örmeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S., and Hindman, S. J.

Published
2014
Full Text
View/download PDF

10. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection

Author

Zeuzem, S, Foster, G, Wang, S, Asatryan, A, Gane, E, Feld, J, Asselah, T, Bourliere, M, Ruane, P, Wedemeyer, H, Pol, S, Flisiak, R, Poordad, F, Chuang, W, Stedman, C, Flamm, S, Kwo, P, Dore, G, Sepulveda-Arzola, G, Roberts, S, Soto-Malave, R, Kaita, K, Puoti, M, Vierling, J, Tam, E, Vargas, H, Bruck, R, Fuster, F, Paik, S, Felizarta, F, Kort, J, Fu, B, Liu, R, Ng, T, Pilot-Matias, T, Lin, C, Trinh, R, Mensa, F, Zeuzem S., Foster G. R., Wang S., Asatryan A., Gane E., Feld J. J., Asselah T., Bourliere M., Ruane P. J., Wedemeyer H., Pol S., Flisiak R., Poordad F., Chuang W. -L., Stedman C. A., Flamm S., Kwo P., Dore G. J., Sepulveda-Arzola G., Roberts S. K., Soto-Malave R., Kaita K., Puoti M., Vierling J., Tam E., Vargas H. E., Bruck R., Fuster F., Paik S. -W., Felizarta F., Kort J., Fu B., Liu R., Ng T. I., Pilot-Matias T., Lin C. -W., Trinh R., Mensa F. J., Zeuzem, S, Foster, G, Wang, S, Asatryan, A, Gane, E, Feld, J, Asselah, T, Bourliere, M, Ruane, P, Wedemeyer, H, Pol, S, Flisiak, R, Poordad, F, Chuang, W, Stedman, C, Flamm, S, Kwo, P, Dore, G, Sepulveda-Arzola, G, Roberts, S, Soto-Malave, R, Kaita, K, Puoti, M, Vierling, J, Tam, E, Vargas, H, Bruck, R, Fuster, F, Paik, S, Felizarta, F, Kort, J, Fu, B, Liu, R, Ng, T, Pilot-Matias, T, Lin, C, Trinh, R, Mensa, F, Zeuzem S., Foster G. R., Wang S., Asatryan A., Gane E., Feld J. J., Asselah T., Bourliere M., Ruane P. J., Wedemeyer H., Pol S., Flisiak R., Poordad F., Chuang W. -L., Stedman C. A., Flamm S., Kwo P., Dore G. J., Sepulveda-Arzola G., Roberts S. K., Soto-Malave R., Kaita K., Puoti M., Vierling J., Tam E., Vargas H. E., Bruck R., Fuster F., Paik S. -W., Felizarta F., Kort J., Fu B., Liu R., Ng T. I., Pilot-Matias T., Lin C. -W., Trinh R., and Mensa F. J.

Abstract

BACKGROUND Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week and 12-week courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection. METHODS We conducted two phase 3, randomized, open-label, multicenter trials. Patients with genotype 1 infection were randomly assigned in a 1:1 ratio to receive oncedaily glecaprevir-pibrentasvir for either 8 or 12 weeks. Patients with genotype 3 infection were randomly assigned in a 2:1 ratio to receive 12 weeks of treatment with either glecaprevir-pibrentasvir or sofosbuvir-daclatasvir. Additional patients with genotype 3 infection were subsequently enrolled and nonrandomly assigned to receive 8 weeks of treatment with glecaprevir-pibrentasvir. The primary end point was the rate of sustained virologic response 12 weeks after the end of treatment. RESULTS In total, 1208 patients were treated. The rate of sustained virologic response at 12 weeks among genotype 1-infected patients was 99.1% (95% confidence interval [CI], 98 to 100) in the 8-week group and 99.7% (95% CI, 99 to 100) in the 12-week group. Genotype 3-infected patients who were treated for 12 weeks had a rate of sustained virologic response at 12 weeks of 95% (95% CI, 93 to 98; 222 of 233 patients) with glecaprevir-pibrentasvir and 97% (95% CI, 93 to 99.9; 111 of 115) with sofosbuvir-daclatasvir; 8 weeks of treatment with glecaprevir-pibrentasvir yielded a rate of 95% (95% CI, 91 to 98; 149 of 157 patients). Adverse events led to discontinuation of treatment in no more than 1% of patients in any treatment group. CONCLUSIONS Once-daily treatment with glecaprevir-pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis. (Funded by AbbVie

Published
2018

18. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.

Author

Op den Brouw M., Jump B., Gaggar A., Flaherty J., Buti M., Marcellin P., Wong D.K., Sievert W., Buggisch P., Petersen J., Flisiak R., Manns M., Kaita K., Krastev Z., Lee S.S., Cathcart A.L., Crans G., Op den Brouw M., Jump B., Gaggar A., Flaherty J., Buti M., Marcellin P., Wong D.K., Sievert W., Buggisch P., Petersen J., Flisiak R., Manns M., Kaita K., Krastev Z., Lee S.S., Cathcart A.L., and Crans G.

Abstract

Background & Aims: Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF treatment for up to 10 years in a well-described cohort of CHB patients. Method(s): Hepatitis B e antigen (HBeAg)-negative and HBeAg-positive patients from two randomised, double-blind trials (ClinicalTrials.gov: NCT00117676 and NCT00116805) completed 48 weeks of randomised treatment with TDF or adefovir dipivoxil. A subset of these patients was then eligible to receive open-label TDF treatment for up to 10 years. At Year 10, patients were assessed for virological suppression, alanine aminotransferase (ALT) normalisation, serological response, safety and tolerability. Result(s): Of 641 randomised and treated patients, 585 (91%) entered the open-label extension phase with 203 (32%) patients completing Year 10 of the study. At Year 10, 118/118 (100%) of HBeAg-negative patients and 78/80 (98%) of HBeAg-positive patients with available data achieved hepatitis B virus (HBV) DNA < 69 IU/mL, while 88/106 (83%) and 60/77 (78%) patients achieved ALT normalisation, respectively. Of the 23 patients with HBeAg status available at Year 10, 12 (52%) and six (27%) experienced HBeAg loss and seroconversion, respectively. No resistance to TDF was documented up to Year 10. In the period between Year 8 and Year 10, the safety profile of TDF was similar to previous reports, with few patients experiencing renal- or bone-related adverse events. Conclusion(s): Over 10 years, TDF had a favourable safety profile, was well tolerated, and resulted in continued maintenance of virological suppression with no documented resistance.Copyright © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Published
2019

22. Response of electromagnetic conductivity meter to soil salinity and soil-water content

Author

Hanson, B.R. and Kaita, K.

Subjects
Soil moisture -- Research, Soils, Salts in -- Research, Electrical conductivity -- Research, Engineering and manufacturing industries, Science and technology
Abstract

The effect of soil salinity and soil-water content on the apparent soil electrical conductivity as measured with the EM-38 electromagnetic conductivity meter has been investigated. Results showed substantial changes in the meter's readings as soil-water content changed. The higher the soil salinity, the more sensitive the meter's readings were to changes in soil-water content. A linear relationship existed between soil-water content and apparent electrical conductivity for each level of soil salinity over the range of measured soil-water contents.

Published
1997

24. ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis

Author

Foster, G.R., primary, Gane, E., additional, Asatryan, A., additional, Asselah, T., additional, Ruane, P.J., additional, Pol, S., additional, Poordad, F., additional, Stedman, C.A., additional, Dore, G., additional, Roberts, S.K., additional, Kaita, K., additional, Vierling, J., additional, Vargas, H.E., additional, Kort, J., additional, Lin, C.-W., additional, Liu, R., additional, Ng, T., additional, and Mensa, F., additional

Published
2017
Full Text
View/download PDF

25. Telaprevir for previously untreated chronic hepatitis C virus infection

Author

Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., ADVANCE Study Team: Gadano A., Terg R., Bell S., Cheng W., Crawford D., Dore G., MacDonald G., Roberts S., Gschwantler M., Laferl H., Maieron A., Heathcote J., Kaita K., Myers R., Sherman M., Yoshida E., Barange K., Couzigou P., Pawlotsky J. M., Pol S., Serfaty L., Trépo C., Zarski J. P., Berg T., Buggisch P., Diepolder H., Goeser T., Mauss S., Rasenack J., Schmidt W., Wedemeyer H., Baruch Y., Ben Ari Z., Maor Y., Safadi R., Zuckerman E., Colombo M., Baka Cwierz B., Gladysz A., Janczewska Kazek E., Jablkowski M., Krycka W., Diago M., Esteban Mur R., Sanchez Tapias J., Brown A., Fox R., Afdhal N., Arora S., Bennett M., Bernstein D., Bloomer J., Bochan M., Bonkovsky H., Brady C., Brown R., Bzowej N., Cochran J., Chasen R., Davis G., De Jesus E., Di Bisceglie A., Dienstag J., Dieterich D., Etzkorn K., Everson G., Fried M., Freilich B., Ghalib R., Gitlin N., Godofsky E., Gordon S., Hassanein T., Jacobson I., Javadi F., Jonas M., Kilby A., Kwo P., Lawitz E., Lebovics E., Lee W., Luketic V., Maillard M., Monto A., Morgan T., Min A., Murphy M., Nelson D., Northup P., Nyberg L., Pockros P., Poordad F., Poulos J., Reddy R., Rodriguez Torres M., Satyanarayana R., Schiff E., Schwartz H., Shaikh O., Sheikh M., Sherman K., Smith J., Strohecker J., Sulkowski M., Szabo G., Te H., Terrault N., Tsai N., Vargas H., Vierling J., Wruble L., Younossi Z., Zein N., ANDREONE, PIETRO, Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S., ADVANCE Study Team: Gadano A., Terg R., Bell S., Cheng W., Crawford D., Dore G., MacDonald G., Roberts S., Gschwantler M., Laferl H., Maieron A., Heathcote J., Kaita K., Myers R., Sherman M., Yoshida E., Barange K., Couzigou P., Pawlotsky J.M., Pol S., Serfaty L., Trépo C., Zarski J.P., Berg T., Buggisch P., Diepolder H., Goeser T., Mauss S., Rasenack J., Schmidt W., Wedemeyer H., Baruch Y., Ben-Ari Z., Maor Y., Safadi R., Zuckerman E., Andreone P., Colombo M., Baka-Cwierz B., Gladysz A., Janczewska-Kazek E., Jablkowski M., Krycka W., Diago M., Esteban-Mur R., Sanchez-Tapias J., Brown A., Fox R., Afdhal N., Arora S., Bennett M., Bernstein D., Bloomer J., Bochan M., Bonkovsky H., Brady C., Brown R., Bzowej N., Cochran J., Chasen R., Davis G., De Jesus E., Di Bisceglie A., Dienstag J., Dieterich D., Etzkorn K., Everson G., Fried M., Freilich B., Ghalib R., Gitlin N., Godofsky E., Gordon S., Hassanein T., Jacobson I., Javadi F., Jonas M., Kilby A., Kwo P., Lawitz E., Lebovics E., Lee W., Luketic V., Maillard M., Monto A., Morgan T., Min A., Murphy M., Nelson D., Northup P., Nyberg L., Pockros P., Poordad F., Poulos J., Reddy R., Rodriguez-Torres M., Satyanarayana R., Schiff E., Schwartz H., Shaikh O., Sheikh M., Sherman K., Smith J., Strohecker J., Sulkowski M., Szabo G., Te H., Terrault N., Tsai N., Vargas H., Vierling J., Wruble L., Younossi Z., and Zein N.

Subjects
Adult, Male, medicine.medical_specialty, CHRONIC HEPATITIS C, Telaprevir, ANTIVIRAL TREATMENT, Serine Proteinase Inhibitors, Hepatitis C virus, Hepacivirus, Interferon alpha-2, medicine.disease_cause, Gastroenterology, Antiviral Agents, Polyethylene Glycols, chemistry.chemical_compound, Young Adult, Double-Blind Method, Internal medicine, Boceprevir, medicine, Humans, Beclabuvir, Aged, business.industry, Ribavirin, Danoprevir, Interferon-alpha, virus diseases, General Medicine, Hepatitis C, Sequence Analysis, DNA, Hepatitis C, Chronic, Middle Aged, Viral Load, medicine.disease, Ombitasvir, Recombinant Proteins, digestive system diseases, Logistic Models, chemistry, Immunology, RNA, Viral, Drug Therapy, Combination, Female, business, Oligopeptides, medicine.drug
Abstract

A B S T R AC T Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients. Methods In this international, phase 3, randomized, double-blind, placebo-controlled trial, we assigned 1088 patients with HCV genotype 1 infection who had not received previous treatment for the infection to one of three groups: a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group), followed by peginterferon–ribavirin alone for 12 weeks if HCV RNA was undetectable at weeks 4 and 12 or for 36 weeks if HCV RNA was detectable at either time point; a group receiving telaprevir with peginterferon–ribavirin for 8 weeks and placebo with peginterferon–ribavirin for 4 weeks (T8PR group), followed by 12 or 36 weeks of peginterferon–ribavirin on the basis of the same HCV RNA criteria; or a group receiving placebo with peginterferon–ribavirin for 12 weeks, followed by 36 weeks of peginterferon–ribavirin (PR group). The primary end point was the proportion of patients who had undetectable plasma HCV RNA 24 weeks after the last planned dose of study treatment (sustained virologic response). Results Significantly more patients in the T12PR or T8PR group than in the PR group had a sustained virologic response (75% and 69%, respectively, vs. 44%; P

Published
2011

26. Strategies to manage hepatitis C virus (HCV) disease burden

Author

Wedemeyer, H, Duberg, A S, Buti, M, Rosenberg, W M, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, A J, Brandão Mello, C E, Bruggmann, P, Calinas, F, Calleja, J L, Cheinquer, H, Christensen, P B, Clausen, M, Coelho, H S M, Cornberg, M, Cramp, M E, Dore, G J, Doss, W, El-Sayed, M H, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, M L G, Ferreira, P R, García-Samaniego, J, Gerstoft, J, Giria, J A, Gonçales, F L, Guimarães Pessôa, M, Hézode, C, Hindman, S J, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, K D E, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, R T, Marotta, P, Mauss, S, Mendes Correa, M C, Moreno, C, Müllhaupt, B, Myers, R P, Nemecek, V, Øvrehus, A L H, Parkes, J, Peltekian, K M, Ramji, A, Razavi, H, Reis, N, Roberts, S K, Roudot-Thoraval, F, Ryder, S D, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, G E, Sperl, J, Stärkel, P, Stauber, R E, Thompson, A J, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, Gower, E, Wedemeyer, H, Duberg, A S, Buti, M, Rosenberg, W M, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, A J, Brandão Mello, C E, Bruggmann, P, Calinas, F, Calleja, J L, Cheinquer, H, Christensen, P B, Clausen, M, Coelho, H S M, Cornberg, M, Cramp, M E, Dore, G J, Doss, W, El-Sayed, M H, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, M L G, Ferreira, P R, García-Samaniego, J, Gerstoft, J, Giria, J A, Gonçales, F L, Guimarães Pessôa, M, Hézode, C, Hindman, S J, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, K D E, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, R T, Marotta, P, Mauss, S, Mendes Correa, M C, Moreno, C, Müllhaupt, B, Myers, R P, Nemecek, V, Øvrehus, A L H, Parkes, J, Peltekian, K M, Ramji, A, Razavi, H, Reis, N, Roberts, S K, Roudot-Thoraval, F, Ryder, S D, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, G E, Sperl, J, Stärkel, P, Stauber, R E, Thompson, A J, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, and Gower, E

Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

Published
2014

27. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Author

Bruggmann, P, Berg, T, Øvrehus, A L H, Moreno, C, Brandão Mello, C E, Roudot-Thoraval, F, Marinho, R T, Sherman, M, Ryder, S D, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, A J, Buti, M, Calinas, F, Calleja, J L, Cheinquer, H, Christensen, P B, Clausen, M, Coelho, H S M, Cornberg, M, Cramp, M E, Dore, G J, Doss, W, Duberg, A S, El-Sayed, M H, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, M L G, Ferreira, P R, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, J A, Gonçales, F L, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, K D E, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, M C, Müllhaupt, B, Myers, R P, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, K M, Ramji, A, Razavi, H, Reis, N, Roberts, S K, Rosenberg, W M, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, G E, Sievert, W, Stärkel, P, Stauber, R E, Thompson, A J, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, Hindman, S J, Bruggmann, P, Berg, T, Øvrehus, A L H, Moreno, C, Brandão Mello, C E, Roudot-Thoraval, F, Marinho, R T, Sherman, M, Ryder, S D, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, A J, Buti, M, Calinas, F, Calleja, J L, Cheinquer, H, Christensen, P B, Clausen, M, Coelho, H S M, Cornberg, M, Cramp, M E, Dore, G J, Doss, W, Duberg, A S, El-Sayed, M H, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, M L G, Ferreira, P R, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, J A, Gonçales, F L, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, K D E, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, M C, Müllhaupt, B, Myers, R P, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, K M, Ramji, A, Razavi, H, Reis, N, Roberts, S K, Rosenberg, W M, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, G E, Sievert, W, Stärkel, P, Stauber, R E, Thompson, A J, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, and Hindman, S J

Abstract

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.

Published
2014

28. P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

Author

Asselah, T., primary, Jensen, D.M., additional, Foster, G.R., additional, Sulkowski, M.S., additional, Ouzan, D., additional, Morano, L., additional, Buynak, R., additional, Agarwal, K., additional, Hassanein, T., additional, Forton, D., additional, Cho, M., additional, Genné, D., additional, Kaita, K., additional, Maieron, A., additional, Preotescu, L., additional, Sarrazin, C., additional, Zehnter, E., additional, Streinu-Cercel, A., additional, Stern, J.O., additional, Datsenko, Y., additional, Drulak, M., additional, Voss, F., additional, Quinson, A.-M., additional, and Ferenci, P., additional

Published
2014
Full Text
View/download PDF

29. P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

Author

Asselah, T., primary, Jensen, D.M., additional, Foster, G.R., additional, Sulkowski, M.S., additional, Ouzan, D., additional, Morano, L., additional, Buynak, R., additional, Agarwal, K., additional, Hassanein, T., additional, Forton, D., additional, Negro, F., additional, Genné, D., additional, Kaita, K., additional, Maieron, A., additional, Preotescu, L., additional, Sarrazin, C., additional, Zehnter, E., additional, Romero-Gómez, M., additional, Stern, J.O., additional, Quinson, A.-M., additional, Drulak, M., additional, Garcia, M., additional, Voss, F., additional, Böcher, W., additional, and Ferenci, P., additional

Published
2014
Full Text
View/download PDF

30. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B

Author

Marcellin, P. (P.), Heathcote, E.J. (Jenny), Buti, M. (Maria), Gane, E. (Ed), Man, R.A. (Robert) de, Krastev, Z. (Zahary), Germanidis, G. (George), Lee, S.S. (Sam ), Flisiak, R. (Robert), Kaita, K. (Kelly), Manns, M.P. (Michael), Kotzev, I. (Iskren), Tchernev, K. (Konstantin), Buggisch, P. (Peter), Weilert, F. (Frank), Kurdas, O.O. (Oya Ovung), Shiffman, M.L. (Mitchell), Trinh, H. (Huy), Washington, M.K. (Mary Kay), Anderson, J.K. (Jane), Sorbel, J. (Jeff), Snow-Lampart, A. (Andrea), Mondou, E. (Elsa), Quinn, J. (Joe), Rousseau, M.F. (Francois), Marcellin, P. (P.), Heathcote, E.J. (Jenny), Buti, M. (Maria), Gane, E. (Ed), Man, R.A. (Robert) de, Krastev, Z. (Zahary), Germanidis, G. (George), Lee, S.S. (Sam ), Flisiak, R. (Robert), Kaita, K. (Kelly), Manns, M.P. (Michael), Kotzev, I. (Iskren), Tchernev, K. (Konstantin), Buggisch, P. (Peter), Weilert, F. (Frank), Kurdas, O.O. (Oya Ovung), Shiffman, M.L. (Mitchell), Trinh, H. (Huy), Washington, M.K. (Mary Kay), Anderson, J.K. (Jane), Sorbel, J. (Jeff), Snow-Lampart, A. (Andrea), Mondou, E. (Elsa), Quinn, J. (Joe), and Rousseau, M.F. (Francois)

Abstract

Background: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. Methods: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of <400 copies per milliliter), histologic improvement, serologic response, normalization of alanine aminotransferase levels, and development of resistance mutations. Results: At week 48, in both studies, a significantly higher proportion of patients receiving tenofovir DF than of those receiving adefovir dipivoxil had reached the primary end point (P<0.001). Viral suppression occurred in more HBeAg-negative patients receiving tenofovir DF than patients receiving adefovir dipivoxil (93% vs. 63%, P<0.001) and in more HBeAg-positive patients receiving tenofovir DF than patients receiving adefovir dipivoxil (76% vs. 13%, P<0.001). Significantly more HBeAg-positive patients treated with tenofovir DF than those treated with adefovir dipivoxil had normalized alanine aminotransferase levels (68% vs. 54%, P = 0.03) and loss of hepatitis B surface antigen (3% vs. 0%, P = 0.02). At week 48, amino acid substitutions within HBV DNA polymerase associated with phenotypic resistance to tenofovir DF or other drugs to treat HBV infection had not developed in any of the patients. Tenofovir DF produced a similar HBV DNA response in patients who had previously received lamivudine and in those who had not. The safety profil

Published
2008
Full Text
View/download PDF

32. Numerical Simulation of Flow over an Axisymmetric body in Free Flight

Author

Nishikawa, N. (author), Kaita, K. (author), Ishide, T. (author), Nishikawa, N. (author), Kaita, K. (author), and Ishide, T. (author)

Abstract

Flow field around a projectile after thrust has been stopped and in inertia flight is studied numerically by a finite difference scheme. This study aims at clarifying the mechanism of free flight, which is generated and developed by rotation of body and gravity. Among two types of projectiles concerned a three-dimensional flow around the slender body, such as aircraft body, rocket .causes drastic variation with high angle of attack and has considerable influence on the aerodynamic behavior. The flow over a paraboloidal-nose cylinder at pitching rotation is considered with inertia translating motion and the flow symmetry assumption . Another example is a oblate spheroid, and in these examples the initial condition is the flow at steady ‘flight’. In present numerical study coordinate system fixed on the body ,with non-inertial frame of reference, which yields additional terms in Navier Stokes equation. The dual-time pseudo compressibility code is applied for incompressible flow. The Newton’s 2nd law is used with the balance of aerodynamic force and gravity together with angular momentum equation. For the slender body the initial incidence angle is horizontal or 40deg. For the spheroid the initial motion is set either upwardi: counter to gravity-direction or downward one. For Reynolds numbers lower than 10000, the behavior of flow field and varying incidence angle will be discussed as well asthe trajectory of body.

Published
2006

34. 31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS

Author

Rodriguez-Torres, M., primary, Lawitz, E., additional, Conway, B., additional, Kaita, K., additional, Sheikh, A.M., additional, Ghalib, R., additional, Adrover, R., additional, Cooper, C., additional, Silva, M., additional, Rosario, M., additional, Bourgault, B., additional, Proulx, L., additional, and McHutchison, J.G., additional

Published
2010
Full Text
View/download PDF

38. Tenofovir DF (TDF) showed superior antiviral efficacy to adefovir dipivoxil in a randomized, double-blind, study for the treatment of HBeAg-negative chronic hepatitis B (CHB)

Author

Rizzetto, M., primary, Marcellin, P., additional, Andreone, P., additional, Buti, M., additional, Krastev, Z., additional, Germanidis, G., additional, Kaita, K., additional, Kotzev, I., additional, Buggisch, P., additional, Weilert, F., additional, Sorbel, J., additional, Anderson, J., additional, Mondou, E., additional, and Rousseau, F., additional

Published
2008
Full Text
View/download PDF

41. [779] ANTIVIRAL RESPONSE AT WEEK 12 FOLLOWING COMPLETION OF TREATMENT WITH ALBINTERFERON a-2b PLUS RIBAVIRIN IN GENOTYPE 1, IFN-NAIVE, CHRONIC HEPATITIS C PATIENTS

Author

Zeuzem, S., primary, Benhamou, Y., additional, Bain, V., additional, Shouval, D., additional, Pianko, S., additional, Flisiak, R., additional, Grigorescu, M., additional, Rehak, V., additional, Yoshida, E., additional, Kaita, K., additional, Cronin, P., additional, Pulkstenis, E., additional, Subramanian, M., additional, and McHutchison, J., additional

Published
2007
Full Text
View/download PDF

43. [127] Phil PROOF OF CONCEPT STUDY OF CELGOSIVIR IN COMBINATION WITH PEGINTERFERON o-2b AND RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE-1 NON-RESPONDER PATIENTS

Author

Kaita, K., primary, Yoshida, E., additional, Kunimoto, D., additional, Anderson, F., additional, Morris, S., additional, Marotta, P., additional, Scully, L., additional, Peltekian, K., additional, Enns, R., additional, Diaz-Mitoma, F., additional, Lee, S., additional, Worobetz, L., additional, Pankovich, J., additional, and Petersen, A.K., additional

Published
2007
Full Text
View/download PDF

48. O.127 Phase 2b interim (week 12) results of albumin interferon alpha-2b combined with ribavirin in IFN-naïve, genotype 1 chronic hepatitis C infection

Author

Benhamou, Y., primary, Zeuzem, S., additional, Shouval, D., additional, Bain, V., additional, Pianko, S., additional, Flisiak, R., additional, Grigorescu, M., additional, Rehak, V., additional, Yoshida, E., additional, Kaita, K., additional, Hezode, C., additional, Neumann, A.U., additional, Subramanian, M., additional, and McHutchison, J., additional

Published
2006
Full Text
View/download PDF

49. Long-term safety beyond 48 weeks of adefovir dipivoxil (ADV) 10 Mg once daily for chronic hepatitis B (CHB): An integrated analysis of two phase III studies

Author

Tong, M., primary, Shiffman, M., additional, Heathcote, J., additional, Gish, R., additional, Jeffers, L., additional, Sacks, S., additional, Kaita, K., additional, Fallis, R., additional, Wollman, M., additional, James, C., additional, Doren, S. Van, additional, Fry, J., additional, Chen, S.S., additional, and Brosgart, C., additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results